Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

By H. Dvorak. Journal of Clinical Oncology, 2002

1,616 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/19ba575c91b2f6e926eb081605d5d09f917535e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, positive): “Initially discovered as vascular permeability factor by Harold Dvorak and colleagues (Dvorak, 2002), VEGF turned out to be a key survival factor for endothelial cells.”
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007, background): “AZD2171 Induces a Rapid Onset of Functional Vascular Normalization VEGF is a potent vascular permeability factor (Dvorak, 2002; Senger et al., 1983).”
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors (2005, background): “Key among these is VEGF (Ferrara, 2000, 2002; Dvorak, 2002).”
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. (2004, background): “…a diametermay enhance the damaging effect of radiation to tumor vessels of 2–2.5 mm (defined as day 0), treatment was started with either the mono-(Dvorak, 2002; Ferrara et al., 2004; Kerbel and Folkman, 2002). clonal VEGFR2-specific antibody DC101 (rat anti-mouse; ImClone Systems However, the…”
VEGF-targeted therapy: mechanisms of anti-tumour activity (2008, background): “VEGF biology The mammalian VEGF family consists of five glycoproteins referred to as VEGFA , VEGFB , VEGFC , VEGFD (also known as FIGF ) and placenta growth factor (PlGF, also known as PGF”
Angiogenesis in Cancer (2006, neutral): “…3Hita Saiseikai Hospital, Oita, Japan Correspondence: Naoyo Nishida Department of Pathology, Kurume University School of Medicine 67, Asahimachi, Kurume, Fukuoka 830-0011, Japan Tel +81 942 31 7546 Fax +81 942 32 0905 Email naoji@med.kurume-u.ac.jp Vascular Health and Risk Management 2006:2(3)214”
Vascular Endothelial Growth Factor and Angiogenesis (2004, background): “…outcome, none of the techniques used to quantitate tumor VEGF-A expression in solid tumors are routine, and at present it is uncertain if such studies were widely undertaken that they would be clinically useful or cost-effective for predicting outcomes in individual patients (Dvorak, 2002).”
Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. (2006, background): “Dvorak, H. F. (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor”